An immune army already stationed at the tumor's gates, waiting to be mobilized.
For decades, the immune system's most ancient defenders — macrophages, the original 'big eaters' named by a Nobel laureate in 1908 — were overlooked in the story of cancer. Now, researchers in Sydney have filmed these cells doing something no one had witnessed before: consuming living melanoma cells, unprompted by T cells or antibodies, as if quietly waging a war the rest of medicine had not yet noticed. The discovery, emerging from a question about why some patients survive and others do not, suggests that the architecture of immunity around a tumor may be far more complex — and far more hopeful — than the prevailing story allowed.
- Immune checkpoint inhibitors have transformed melanoma treatment, yet they fail entirely in 'cold' tumors where the cancer's microenvironment walls out T cells — leaving a significant portion of patients without options.
- Using real-time imaging inside living tissue, researchers caught macrophages actively engulfing live cancer cells — a feat never before observed in a living organism, and one that bypassed the immune system's usual chain of command.
- A specific subtype of macrophage, marked by the protein CD169 and clustered at the edges of tumors like sentinels, was found to suppress tumor growth — when these cells were removed, cancers grew larger.
- The same CD169-expressing macrophages were identified in tissue samples from actual melanoma patients, suggesting this is not a laboratory curiosity but a real mechanism operating in human disease.
- The critical unknown now is whether these macrophages silently dispose of cancer cells or broadcast a danger signal to T cells — cracking that code could explain immunotherapy's inconsistency and point toward treatments that work for everyone.
A dermatologist from Japan and an immunologist in Sydney shared a stubborn question: why do some melanoma patients respond dramatically to immune checkpoint inhibitors while others receive no benefit at all? These drugs have reshaped treatment for the deadliest form of skin cancer over fifteen years, yet their success remains maddeningly uneven. Rather than study the drugs themselves, the team at Sydney's Garvan Institute turned to the immune landscape surrounding the tumor.
Oncologists call resistant cases 'cold' tumors — cancers whose microenvironments actively prevent T cells from penetrating and destroying malignant tissue. The assumption had long been that warming these tumors, flooding them with T cells, was the answer. But the researchers suspected something else was at work, and they looked toward macrophages — immune cells so unglamorous they had been largely ignored in cancer research despite being discovered more than a century ago. In 1908, Ilya Mechnikov won the Nobel Prize for identifying phagocytosis, the process by which cells engulf others, and named the responsible cells macrophages, from the Greek for 'big eaters.' Since then, they had been cast as quiet custodians, clearing debris rather than fighting disease.
When the team examined skin samples closely, they found that macrophages were not a uniform population. One particular subtype, identified by a protein marker called CD169, clustered in the deeper skin layer and arranged themselves around melanoma tumors like a defensive perimeter. Depleting these cells caused tumors to grow larger — evidence that the macrophages had been actively suppressing cancer growth.
To see what these cells were actually doing, the researchers used intravital two-photon microscopy, an advanced technique that captures biological events unfolding in living tissue in real time. What they saw had never been observed before: macrophages directly engulfing live melanoma cells, with no assistance from T cells or antibodies. The findings, published in the Journal of Experimental Medicine, pointed to an entirely overlooked mechanism of tumor control.
Colleagues at the Melanoma Institute Australia confirmed the same CD169-expressing macrophages positioned at tumor edges in tissue from actual patients — suggesting this is not a laboratory artifact but a genuine feature of human disease. Yet a puzzle remains: macrophages can either silently dispose of what they consume or display it as a warning signal to recruit T cells. What governs that choice is still unknown. If researchers can decode how these cells communicate danger, they may finally understand immunotherapy's inconsistency — and learn how to extend its benefits to every patient. The implications reach well beyond melanoma, since macrophages are abundant in most solid tumors, representing an immune army already stationed at the gates, waiting to be mobilized.
A dermatologist in Japan and an immunologist in Sydney had a question that wouldn't leave them alone: why do some melanoma patients respond dramatically to the newest cancer drugs while others see no benefit at all? The drugs in question—immune checkpoint inhibitors—have transformed treatment for the most dangerous form of skin cancer over the past 15 years. Yet their success is maddeningly inconsistent. When Yuki, the dermatologist, joined Tri Phan's laboratory at the Garvan Institute to investigate, they began looking not at the drugs themselves, but at the immune system's architecture around the tumor.
Oncologists have a term for tumors that resist these therapies: cold tumors. In these cases, the cancer's microenvironment actively blocks T cells—the immune system's celebrated assassins—from penetrating and destroying malignant tissue. The prevailing assumption was that if you could somehow make these cold tumors hot, flooding them with active T cells, the immunotherapy would work. But Phan's team suspected something else might be at play. They turned their attention to macrophages, a class of immune cell so unglamorous that it had largely been ignored in cancer research despite being discovered over a century ago.
In 1908, Russian zoologist Ilya Mechnikov won the Nobel Prize for identifying phagocytosis—the process of cells engulfing and consuming other cells—and named the cells responsible macrophages, from the Greek for big eaters. Since then, they've been cast as the immune system's custodians, quietly clearing away cellular debris and tissue damage. Unlike T cells and B cells, which patrol the bloodstream, macrophages are tissue-resident; they stay put in one location. When the researchers examined skin samples closely, they discovered that macrophages were not a uniform population. Different types lived in different layers. One particular variety, identified by a protein marker called CD169, clustered in the deeper skin layer called the hypodermis, and they arranged themselves around melanoma tumors like a defensive perimeter. When the team depleted these cells, tumors grew larger, suggesting the macrophages had been holding cancer growth in check.
To see what these CD169-positive macrophages were actually doing, the researchers deployed intravital two-photon microscopy—an advanced imaging technique that allows scientists to watch biological processes unfold in living tissue in real time. What they observed was striking: the macrophages were actively engulfing live melanoma cells. The team had previously watched macrophages consume dead cells in laboratory conditions, but they had never witnessed them attack and consume a living cancer cell in a living organism. Even more remarkable, this immune assault was occurring without any involvement from T cells or antibodies produced by B cells—the immune players traditionally credited with cancer defense. The findings, published in the Journal of Experimental Medicine, suggested that an entirely different mechanism of tumor control was operating, one that had been overlooked for decades.
The researchers confirmed their observations were not merely a laboratory artifact. Colleagues at the Melanoma Institute Australia examined tissue samples from actual melanoma patients and identified the same populations of CD169-expressing macrophages positioned at tumor edges, suggesting they perform a similar protective function in human disease. But the discovery raised a new puzzle: macrophages serve dual roles in the immune system. They can silently dispose of cellular debris without alerting the broader immune response, or they can display what they've consumed like a biological warning flag, directing T cells to the site of danger. What determines which path a macrophage takes remains unclear. The strategic positioning of CD169-expressing macrophages around tumors suggests they may be the decision-makers in this process.
The implications extend far beyond melanoma. Macrophages are abundant in most solid tumors—glioblastoma, breast cancer, and many others. They represent, in effect, an immune army already stationed at the tumor's gates, waiting to be mobilized. The next phase of research will focus on understanding precisely how these macrophages consume live cancer cells and how they communicate that threat to T cells. If scientists can decode those signals and learn to amplify them, they may finally understand why checkpoint inhibitors work for some patients and not others—and how to make them work for all.
Citas Notables
We had never seen them eat a live melanoma cell in a model organism before—and it was happening without T cells or antibodies.— Research team, Journal of Experimental Medicine
La Conversación del Hearth Otra perspectiva de la historia
Why did it take so long to notice macrophages were doing this work? They've been around since 1908.
Because they're tissue-resident. T cells and B cells move through the blood, visible and obvious. Macrophages stay in one place, quietly working. In cancer research, we've been obsessed with the cells that patrol and hunt. We overlooked the ones already standing guard.
So when you say the macrophages were "nibbling" live cancer cells—what does that actually look like under the microscope?
It's not violent. It's methodical. The macrophage extends itself around the cancer cell, engulfing it piece by piece. We'd seen them do this to dead debris countless times. Watching them do it to something alive, something fighting back, was entirely different.
The cold tumor problem—is this the answer to why checkpoint inhibitors fail?
It's part of the answer. We think so. The macrophages might be the key to waking up the T cells. But we still don't know what makes a macrophage decide to raise the alarm versus just cleaning up quietly.
If macrophages are in most solid tumors, why haven't we been trying to weaponize them already?
Because we didn't know they were capable of this. We thought they were housekeepers. Now we know they're also hunters. That changes everything about how we might design new treatments.
What happens next in your lab?
We need to understand the conversation between macrophages and T cells. How does a macrophage tell a T cell there's danger? Once we know that language, we can amplify it.